Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
NCT04905121 · Beckley Psytech Limited
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Percentage of patients with treatment emergent AEs (TEAES)
Measured over From first dose administered through to the last follow up visit, approximately 39 days
Treatment-related changes in Paired Associates Learning (PAL) scores and evaluation of dose response
Measured over From first dose administered until the las dose administered, approximately 11 days
Treatment-related changes in Spatial Working Memory (SWM) scores and evaluation of dose response
Measured over From first dose administered until the las dose administered, approximately 11 days
Treatment-related changes in Reaction Time Index (RTI) scores and evaluation of dose response
Measured over From first dose administered until the las dose administered, approximately 11 days
Treatment-related changes in Rapid Visual Information Processing (RVP) scores and evaluation of dose response
Measured over From first dose administered until the las dose administered, approximately 11 days
Change in frequency of headache attacks
Measured over From screening until the follow up visit, approximately 39 days
Change in duration of headache attacks
Measured over From screening until the follow up visit, approximately 39 days
Change in intensity of headache attacks
Measured over From screening until the follow up visit, approximately 39 days
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
1 study site
| Facility | City | Region | Country |
|---|---|---|---|
| King's College London | London | — | United Kingdom |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT04905121 on ClinicalTrials.gov →
Last updated in the registry 2022-10-12. Registry records change; this page reflects the data build of 2026-08-25.
Related